Compounded GLP-1s After the Shortage Ended: What Changed, and What's Legal Now

Compounded GLP-1s — semaglutide and tirzepatide mixed by a pharmacy rather than manufactured by Novo Nordisk or Lilly — became a huge, cheap parallel market during 2023–2024. People paid a few hundred dollars a month instead of over a thousand, and telehealth clinics sold them at scale. Most of those buyers never learned why that market was legally able to exist, which means most of them also missed the moment the ground shifted under it.

Here is what actually happened, stated plainly, without either the "compounding is fraud" scare or the "it's just cheaper Ozempic" spin.

Compounding was riding on an official shortage

U.S. law generally does not allow pharmacies to mass-produce copies of an FDA-approved, patent-protected drug. There's a specific exception: when the FDA lists a drug as being in shortage, compounding pharmacies are permitted to make versions of it to meet demand the manufacturer can't. That shortage listing was the entire legal engine behind compounded GLP-1s.

Both drugs were on that list. And both came off it:

• Tirzepatide shortage was declared resolved in December 2024.
• Semaglutide shortage was declared resolved in February 2025.

When a shortage resolves, the exception that let pharmacies mass-compound the drug narrows sharply. This isn't a gray area of opinion — it's the mechanism the whole market depended on, switching off.

What's still legal, and what isn't

This is the part that gets flattened into slogans, so here's the nuance:

• Large-scale compounding to substitute for the brand — the "just get compounded instead, it's the same and cheaper" model — lost its shortage justification when the lists cleared. That's the piece that changed most.
• Traditional, patient-specific compounding still exists under longstanding rules — for example, when a specific patient has a documented clinical need the manufactured product can't meet (a genuine allergy to an inactive ingredient, a dose the commercial product doesn't come in). That is a narrow, individualized lane, not a bulk-supply channel. "My clinic offers a personalized dose" is sometimes this — and sometimes just marketing language wrapped around a standard formulation.
• Compounded is not, and never was, FDA-approved. This is the single most important sentence in the whole topic. A compounded product does not go through the FDA review that tests a specific formulation's safety, purity, and consistency. That's true regardless of shortage status. You are trading the FDA's manufacturing guarantee for a lower price.

I laid out what "not FDA-approved" actually means — and what it doesn't — in a separate piece, because the phrase gets used to mean both more and less than it does.

Why the price gap exists (and what you give up for it)

Compounded semaglutide typically runs around from about $69 a month and compounded tirzepatide around from about $99 a month, versus over a thousand dollars list for the brands. That gap is real, and for someone with no coverage it's the difference between treatment and none.

But the price reflects what's removed:

• No FDA-approved formulation. Purity, concentration, and consistency depend on the individual pharmacy, not a reviewed manufacturing standard.
• Vial-and-syringe dosing. Most compounded product comes as a vial you draw from, not a metered pen — which reintroduces the milligram-versus-units conversion error the FDA has warned causes overdoses. The pen engineered that risk away; the vial hands it back.
• Variable concentration between refills. A new batch or a new pharmacy can change the concentration, and a dose that was safe last month can be wrong this month if you don't re-check.

If you're weighing the compounded route, the current honest breakdowns are here for compounded semaglutide and compounded tirzepatide — including what to ask the pharmacy about concentration and sourcing.

What to actually do with this

If you're currently on compounded GLP-1: don't panic-stop, but do have a plan. The shortages resolving means the cheap bulk-compounded supply is on less certain legal footing than when you started, and it may narrow or change. Talk to your prescriber about whether a manufacturer self-pay program now closes enough of the price gap to move to the FDA-approved product — because the brands also dropped their cash prices in 2025–2026, and the math that made compounding a no-brainer in 2023 is not the same math today.

If you're considering it now: go in knowing you're buying a non-FDA-approved product whose legal shortage rationale has ended, usually in a form that reintroduces dosing risk. That can still be a reasonable, informed choice for someone with no coverage and no affordable alternative. It should be an informed one, not a "it's basically the same drug for less" one — because on the two things the FDA approval actually certifies, it isn't the same.

The one-line version

Compounded GLP-1s existed at scale because of an official FDA shortage; that shortage ended (tirzepatide December 2024, semaglutide February 2025), which narrowed the legal basis for mass-compounding. Compounded product was never FDA-approved and usually comes in a form that reintroduces dosing risk. It can still make sense for the uninsured — but the brand cash prices fell far enough that the decision is worth re-running from scratch, not carried over from 2023.

Shortage-resolution dates and price ranges verified July 2026. Compounded medications are not FDA-approved. This is general information, not medical or legal advice.